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Recognising and accurately coding reversal of type 2 diabetes is key to improving outcomes and 
reducing healthcare costs, argue Louise McCombie and colleagues 
Type 2 diabetes, generally perceived as progressive and incurable, now affects 5-10% of the 
population, about 3.2 million people in the UK.1 Until complications develop, most patients are 
managed entirely within primary care, with diabetes comprising a major part of general practice 
activity. About 10% of total UK NHS expenditure goes on treating diabetes, and international 
figures suggest that medical costs with diabetes are 2-3 fold greater than the average for age- and 
sex-matched people without diabetes. .1 Application of current clinical guidelines to reduce 
glycated haemoblobin (HbA1c) levels and cardiovascular risks, primarily with drugs and generic 
lifestyle advice, has improved clinical outcomes, but many patients still develop vascular 
complications, and life expectancy remains up to six years shorter than in people without 
diabetes.2 The diagnosis carries important social and financial penalties for individuals, as well 
as poor health prospects.  
Remission of diabetes (no longer having diabetes, at least for a period) is clearly attainable 
for some, possibly many, patients but is currently very rarely achieved or recorded. Greater 
awareness, documentation, and surveillance of remissions should improve health outcomes and 
reduce healthcare costs. 
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Changing management  
In keeping with trends in most medical specialties, diabetes management is beginning to 
focus on reversible underlying disease mechanisms rather than treating symptoms and 
subsequent multisystem pathological consequences.3 4 Both (epi)genetic predisposition and 
ageing have a role in type 2 diabetes, but it is rare without weight gain. 
Lowering blood glucose or HbA1c concentrations remains the primary aim of management, 
as reflected in current clinical guidelines and the actions of licensed drugs. However, 
management and guidelines[Q to A or guidelines? ] focus strongly on use of antidiabetes drugs, 
with only lip service paid to diet and lifestyle advice. The scale of the market for drug therapies, 
and their likely inadequacy, is illustrated by the fact that 488 drugs (excluding insulins) are 
currently licensed worldwide to treat type 2 diabetes, with 70 generic compounds.5 They all 
lower blood glucose and HbA1c significantly, but no trials have yet examined drugs administered 
together with [Q to A or compared drugs with? ] optimal diet and lifestyle advice for weight 
control. 
In contrast, consistent evidence shows that weight loss is associated with extended life 
expectancy for people with diabetes, and that weight loss of around 15kg often produces total 
biochemical remission of type 2 diabetes, restoring beta cell function and.6 7 Recognition that 
accumulation of ectopic fat in the liver and pancreas impairs organ function o cause type 2 
diabetes, but is reversible, has raised awareness that remission is possible.7 Media attention has 
encouraged increasing numbers of people with type 2 diabetes to lose weight and shed the 
diagnosis. Remission produces a strong sense of personal achievement and empowerment, and 
also benefits medical systems because patients no longer require antidiabetes drugs. The UK 
NHS currently spends almost £1bn (€1bn; $1.3bn) a year (£22m a day) on antidiabetes drugs, 
and costs are rising worldwide as diabetes rates and drug prices escalate. 
Criteria for remission of diabetes 
There is no final consensus on the criteria for declaring a remission of diabetes. The 
published criteria, and thus reported remission rates, vary, but all require being below the World 
Health Organization/American Diabetes Association (ADA) diagnostic thresholds for diabetes 
(table 1). Most recent publications, including the Look AHEAD trial [Q to A what is this?],10 
refer to an ADA consensus group statement8 that defined test results below the diagnostic 
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threshold for diabetes as partial remission and remission of “pre-diabetes” as complete 
remission. 
However, using the term partial remission does not fully portray the logic or importance of 
becoming non-diabetic to patients. Although remission of prediabetes is desirable because it 
reduces cardiovascular risk, routine management should aim to help patients escape the 
diagnostic category of diabetes, with its personal burdens and risks of microvascular disease. 
That requires using the WHO diagnostic thresholds for diabetes to establish remission and 
accepting that some patients will continue to have impaired glucose tolerance or prediabetic 
fasting glucose and HbA1c profiles.
8 Measurement of either HbA1c or blood glucose is sufficient 
to identify remission. To avoid misclassification resulting from measurement error or biological 
variation, patients should have two tests results (usually HbA1c) below the diagnostic threshold, 
at least two months apart to confirm remission. This reflects about four months of 
normoglycaemia. Patients in remission should be kept under regular review with annual testing 
(table 1). 
Potential metabolic value of remission 
Clinical outcomes for people with type 2 diabetes are all worse at higher glucose or HbA1c 
concentrations.10 No study has yet reported outcomes for people who achieve remission, but 
good glycaemic control through drug treatment improves microvascular outcomes (retinopathy, 
neuropathy, nephropathy) in both type 1 and type 2 diabetes.11 Reduced cardiac events have also 
been observed in patients with type 2 diabetes after bariatric surgery.12 In contrast, some drug 
trials have indicated increased mortality when HbA1c approaches normal levels, probably 
through hypoglycaemia provoking arrhythmias.13 Look AHEAD, a trial of lifestyle intervention 
in patients with mean diabetes duration of five years, reported 11.5%  remission at 12 months 
with 8.6% weight loss, but that proportion fell by about 30% annually.10 Health outcomes of 
participants have not yet been reported, but the limited evidence and first principles suggest that 
remission of diabetes (without antidiabetes drugs) should enhance overall prognosis, becoming a 
primary management target as early as possible after diagnosis.10 
Coding for health records 
Remission of type 2 diabetes can be inferred from routine records of patients labelled 
diabetic who have non-diabetic biochemical test results (usually HbA1c<48 mmol/mol), when 
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there is no record that antidiabetes drugs are prescribed.14 In the UK, clinicians have used Read 
codes to record patients’ findings and procedures since 198515 but are now converting to the 
international SNOMED system. The basic coding framework will remain, however.  
The Read code [Q to A OK? yes] dictionary includes codes 21263 or 212H for “diabetes 
resolved” and C10P for “diabetes in remission.” Diabetes resolved is used for patients 
misdiagnosed with diabetes or in whom diabetes was secondary to a factor that has since been 
removed, such as withdrawal of steroid treatment. Such patients do not require annual reviews or 
surveillance. Code C10P should be used for patients who have achieved remission of type 2 
diabetes, usually by substantial weight loss. These patients may be considered non-diabetic for 
matters such as insurance, driving, or employment but as the code is diagnostic they will remain 
scheduled for annual reviews and retinal screening programmes. 
Achieving remission 
In the few countries with data, patients are seldom recorded as having diabetes in remission. 
Karter and colleagues found remissions in only 0.14% of 120 000 US patients followed for seven  
years.14 The Scottish Care Information Diabetes database, which includes every patient in 
Scotland, shows that less than 0.1% of those with type 2 diabetes (245/254 208) were coded as 
being in remission in March 2017 (table 2). [Q to A Is there a ref for this data?  No- 
unpblished] 
Lack of agreed criteria and guidance over recoding may have led to hesitation in coding 
remission, but the main reason for the low recording is probably that few patients are attempting 
or achieving remission. Patients and doctors may be unaware that type 2 diabetes can be 
reversed, despite recent publicity. The feasibility of sustained substantial intentional dietary 
weight loss is widely doubted, despite publications of structured approaches using an initial 
formula diet replacement to achieve rapid substantial weight loss and then maintain 12-15 kg 
loss at 12 months and beyond.16 17  
The 2010 guideline of the Scottish Intercollegiate Guidelines Network recommends sustained 
weight loss above 10% of body weight or 15 kg for people with severe and complicated obesity, 
including type 2 diabetes [Q to A OK? No.  I have edited].18 This is difficult to achieve, even 
with bariatric surgery, and only 75-80% of patients who succeed are rewarded with diabetes 
remission.9  
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The drivers and barriers to successful remission are not fully evaluated but are likely to 
include age, body mass index, duration of diabetes, HbA1c concentrations, and drug treatment.
10 
Physical and social environments, emotional states, and self regulatory skills are important 
factors affecting adherence to a weight management intervention.19 It is unknown whether the 
degree of weight loss needed to achieve remission will be the same for Asian people, who 
commonly develop type 2 diabetes at a lower body mass index than people of European origin, 
but probably with similar body fat content. 
Doctors may be understandably reluctant to redefine a patient as “in remission” if they are 
concerned that the remission, dependent on maintaining weight loss, may not persist, and that 
routine recall for annual checks might cease. However, under the remission coding annual 
reviews and screening recalls will continue. Another UK specific factor may have been fear of 
losing the incentive payments for managing diabetes under the Quality and Outcomes 
Framework (QOF). Again, coding “diabetes in remission” retains the diagnostic status so the 
practice payment would continue. 
Diabetes in remission has not been specifically rewarded as a management target in QOF. 
Incentives have been shown to improve care and risk factors in other areas such as asthma and 
cardiovascular disease.[Q to A ref? ]. Forthcoming revisions of QOF in NHS England, and its 
replacement in NHS Scotland, provide opportunities to include diabetes remission as an 
incentivised target. 
Benefits of remission 
Achieving remission has health benefits for patients and removes the burden of daily 
monitoring and treatment, but correct coding of remission has multiple further benefits. It 
removes the stigma of having diabetes and provides a sense of personal achievement and social 
status (box 1).   
Box 1: Benefits of coding remission of diabetes  
For patients 
• Removes personal and social stigmatisation as diseased or “diabetic” 
• Provides a target and a reward for the sustained hard work usually necessary to achieve and 
maintain substantial weight loss 
• May permit life insurance, mortgages, travel insurance, etc without the higher premiums added 
for people with a diagnosis of type 2 diabetes 
• Removes some occupational restrictions 
For epidemiology and health systems 
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• Identifies a valuable indicator of success in healthcare, through national disease register 
monitoring 
• Allows better analysis of long term morbidity and mortality risks 
• Improves resource requirement forecasting 
Diabetes is expensive, both for individuals and for health systems. Evidence is needed on 
health demands and survival after remission, but the demands are likely to be lower. The average 
annual medical costs of type 2 diabetes in the US were calculated at $6414 (£5000; €5400) in 
2007, rising with age to $9061 aged over 64,20 around 2.5 times greater than for people without 
diabetes.21  
The costs are climbing as expensive new drugs are launched, under pharmacocentric clinical 
guidelines. In UK these rising costs are borne by the NHS. In other countries, costs fall to the 
individual. Private health insurance will not usually cover existing diabetes, presenting a barrier 
to optimal medical care. Thus significantly more US adults with diabetes, and the majority aged 
over 65, rely on public insurance such as Medicare. The American Diabetes Association 
provides indicative costs of Medicare cover for people with diabetes. Annual premiums are 
around $1200 plus (optionally) $166 to allow about half of prescription drug costs to be covered. 
Prescription costs are not full covered until an individual has spent over $4950 on drugs in a 
year.22 The 2009 US National Health Interview Survey found that, depending on total household 
income, people aged 18-64 with diabetes spend about $3000 a year on private health insurance 
premiums, or $2000-$6000 a year on healthcare (of poorer quality) if they do not have health 
insurance.23  
Other types of insurance are also more expensive. Life assurance premiums are commonly 
doubled for people with diabetes, adding around £600 a year to an average policy. The 
international online insurance broker moneysupermarket.com currently offers people with type 2 
diabetes equivalent travel policies at almost double the price of that for a person without medical 
problems, adding £20-£30 to the cost of 14 days cover in the US, or more if insulin is needed. At 
present, people who have diabetes in remission are included in the cheaper category (as are 
people with prediabetes). Awareness of tangible cost savings of this kind might help maintain 
weight loss and remission of type 2 diabetes: the promise of rewards and praise for goals 
achieved are key elements in behaviour change strategy. 
Moving forward 
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It is in everybody’s interest to reclassify people with type 2 diabetes when they become non-
diabetic. Official guidelines and international consensus for recording diabetes in remission are 
needed. We have proposed that two non-diabetic test results, at least two months apart, should be 
required, with annual reviews of HbA1c to confirm continuation (table 1). The appropriate 
interval between tests for establishing remission is open to debate. It must be long enough to 
eliminate people with temporary dips in glycaemia but short enough for patients to maintain 
motivation. Having agreed criteria for coding diabetes in remission (C10P in UK) in record 
systems will benefit patients and healthcare planning. Appropriate coding will make it possible 
to monitor progress in achieving remission of type 2 diabetes nationally and internationally and 
to improve predictions of long term health outcomes for patients with a known duration of 
remission. 
Key messages 
Remission of type 2 diabetes is achievable through substantial weight loss but is rarely recorded 
and probably under-reported 
Recognising remission of diabetes can be a powerful motivator for patients to maintain weight 
loss 
 Diagnostic coding of “diabetes in remission” alleviates the social and financial penalties of 
diagnosis for patients while continuing medical surveillance 
Correct coding provides a valuable indication of healthcare success and can inform healthcare 
planning 
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Table 1 Published and proposed criteria for diabetes in remission 
  Criteria for remission Confirmation 
ADA Consensus 
Group8 
 
Partial remission (no longer having diabetes): Both HbA1c 
< 6.5% (<48 mmol/mol) and fasting blood glucose 5.6-6.9 
mmol/L without antidiabetes drugs (time not specified) 
Maintained for 1 year 
   
Complete remission ( no longer having prediabetes): Both 
HbA1c < 6% (<42 mmol/mol) and fasting blood glucose <5.6 
mmol/L without antidiabetes drugs (time not specified)  
Maintained for 1 year 
  
Buchwald et al9 
(systematic review 
after bariatric 
surgery) 
HbA1c < 6% (42 mmol/mol) or fasting blood glucose<5.6 
mmol/L without antidiabetic drugs (time not specified) 
None 
Lean et al 2017  [Q 
to A which ref is this 
] 
proposal for coding 
in routine practice 
Previous diagnosis of type 2 diabetes by WHO criteria. 
HbA1c <6.5% (<48 mmol/mol) or fasting blood 
glucose<7 mmol/l and 2 hour glucose<11 mmol/L after at 
least 2 months without antidiabetes medication   
Two non-diabetic test results, at 
least 2 months apart then 
reviewed annually 
Table 2 Numbers of people in Scotland with different coding categories registered in the SCI 
Diabetes database (March 2017) 
Diabetes category No of patients 
DD-DMT-01 Type 1 diabetes mellitus  30 568 
DD-DMT-02 Type 2 diabetes mellitus  254 208 
DD-DMT-03 Current gestational diabetes  20 
DD-DMT-04 Maturity onset diabetes of youth 212 
DD-DMT-05 Latent autoimmune diabetes of adulthood  196 
DD-DMT-06 Maternally inherited diabetes and deafness  12 
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DD-DMT-07 Neonatal diabetes 9 
DD-DMT-08 Secondary - pancreatic pathology  392 
DD-DMT-09 Secondary - drug induced  242 
DD-DMT-10 Secondary - disease  105 
DD-DMT-11 Impaired glucose tolerance 657 
DD-DMT-12 Impaired fasting glucose  209 
DD-DMT-13 History of gestational diabetes 24 
DD-DMT-14 Stress induced hyperglycaemia (transitory)  23 
DD-DMT-15 Diabetes resolved  587 
DD-DMT-16 Not diabetic  665 
DD-DMT-17 Diabetes in remission  245 
Dd-Dmt-98 Other type of diabetes  432 
DD-DMT-99 Not known 1437 
 
